DTC Genomics Gets Time Before FDA as Agency Considers Regulatory Strategy

During the latter part of a two-day meeting to discuss FDA's stated intent to regulate laboratory-developed tests, most speakers agreed that the FDA should bring consistency to direct-to-consumer genomic risk interpretations, and promulgate standard practices for the industry developed either by an expert advisory panel or a third-party standard-setting body.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.